Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07671833 · ClinicalTrials.gov registry record · Phase 1
A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects
A Phase 1 study, sponsored by Luye Pharma Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07671833: Completed Phase 1 study, sponsored by Luye Pharma Group.
NCT07671833 is a Phase 1 study that has completed, run by Luye Pharma Group. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07671833, a Phase 1 study, has completed, sponsored by Luye Pharma Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening period, baseline visit, and a 28-day safety assessment period with a 7-day/6-night stay in the clinical research unit.
Primary Outcome
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-t) and extrapolated to infinity (AUC0-∞) of LY03015
Interventions
- DRUG LY03015 (LPM3770164 extended-release tablets)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2026-05-27 |
| Phase | Phase 1 |
What the finished NCT07671833 record still lists
NCT07671833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which LY03015 (LPM3770164 extended-release tablets) is the first listed.
NCT07671833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07671833 about?
NCT07671833 is a clinical study titled "A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects". This is an open-label, single-dose, parallel-group study to evaluate the safety, tolerability and pharmacokinetic characteristics of LY03015 in healthy Chinese and Caucasian adult subjects. The duration of study will be around up to 42 days for each participant, including up to 14 days of screening ...
What is the current status of trial NCT07671833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-04-15. Estimated completion is 2026-05-27.
What interventions are being tested in trial NCT07671833?
The interventions under investigation include: LY03015 (LPM3770164 extended-release tablets) (DRUG).
Who is sponsoring clinical trial NCT07671833?
This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07671833's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI